Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases

AIDS. 2014 Jan 14;28(2):288-90. doi: 10.1097/QAD.0000000000000100.

Authors

Angela Colbers¹, Andrea Gingelmaier, Marchina van der Ende, Bart Rijnders, David Burger

Affiliation

¹ aDepartment of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands bDepartment of Obstetrics and Gynecology, Ludwig-Maximillians-University of Munich, Munich, Germany cDepartment of Internal Medicine, Section on Infectiology, Erasmus University Medical Center, Rotterdam, The Netherlands.

PMID: 24413315
DOI: 10.1097/QAD.0000000000000100

No abstract available

Publication types

Case Reports
Clinical Trial, Phase IV
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / administration & dosage
Anti-HIV Agents / pharmacokinetics*
Female
Fetal Blood / chemistry*
HIV Infections / drug therapy*
Humans
Nitriles / administration & dosage
Nitriles / pharmacokinetics*
Plasma / chemistry
Pregnancy
Pregnancy Complications, Infectious / drug therapy*
Pyrimidines / administration & dosage
Pyrimidines / pharmacokinetics*
Rilpivirine
Young Adult

Substances

Anti-HIV Agents
Nitriles
Pyrimidines
Rilpivirine